schliessen

Filtern

 

Bibliotheken

The Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) trial: Clinical and angiographic profile at study entry

Background The optimal revascularization strategy for diabetic patients with multivessel coronary artery disease (MVD) remains uncertain for lack of an adequately powered, randomized trial. The FREEDOM trial was designed to compare contemporary coronary artery bypass grafting (CABG) to percutaneous... Full description

Journal Title: The American heart journal 2012, Vol.164 (4), p.591-599
Main Author: Bansilal, Sameer, MD, MS
Other Authors: Farkouh, Michael E., MD, MSc , Hueb, Whady, MD , Ogdie, May , Dangas, George, MD, PhD , Lansky, Alexandra J., MD , Cohen, David J., MD, MSc , Magnuson, Elizabeth A., ScD , Ramanathan, Krishnan, MB, ChB , Tanguay, Jean-Francois, MD , Muratov, Victoria , Sleeper, Lynn A., ScD , Domanski, Michael, MD , Bertrand, Michel E., MD , Fuster, Valentin, MD, PhD
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: New York, NY: Elsevier Inc
ID: ISSN: 0002-8703
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_1112679740
title: The Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) trial: Clinical and angiographic profile at study entry
format: Article
creator:
  • Bansilal, Sameer, MD, MS
  • Farkouh, Michael E., MD, MSc
  • Hueb, Whady, MD
  • Ogdie, May
  • Dangas, George, MD, PhD
  • Lansky, Alexandra J., MD
  • Cohen, David J., MD, MSc
  • Magnuson, Elizabeth A., ScD
  • Ramanathan, Krishnan, MB, ChB
  • Tanguay, Jean-Francois, MD
  • Muratov, Victoria
  • Sleeper, Lynn A., ScD
  • Domanski, Michael, MD
  • Bertrand, Michel E., MD
  • Fuster, Valentin, MD, PhD
subjects:
  • Abridged Index Medicus
  • Australasia
  • Biological and medical sciences
  • Cardiology. Vascular system
  • Cardiovascular
  • Cardiovascular system
  • Care and treatment
  • Clinical trials
  • Coronary Artery Bypass
  • Coronary Artery Disease - pathology
  • Coronary Artery Disease - surgery
  • Coronary vessels
  • Diabetes
  • Diabetes Mellitus, Type 2 - complications
  • Diabetes Mellitus, Type 2 - drug therapy
  • Diabetes Mellitus, Type 2 - epidemiology
  • Diabetes therapy
  • Diabetes. Impaired glucose tolerance
  • Diabetic Angiopathies - pathology
  • Diabetic Angiopathies - surgery
  • Diabetics
  • Drug therapy
  • Drug-Eluting Stents
  • Endocrine pancreas. Apud cells (diseases)
  • Endocrinopathies
  • Etiopathogenesis. Screening. Investigations. Target tissue resistance
  • Europe
  • Female
  • Heart attacks
  • Humans
  • Investigative techniques, diagnostic techniques (general aspects)
  • Male
  • Medical research
  • Medical sciences
  • Medicine, Experimental
  • Middle Aged
  • Mortality
  • Myocardial Infarction - prevention & control
  • North America
  • Radiodiagnosis. Nmr imagery. Nmr spectrometry
  • South America
  • Stroke - prevention & control
ispartof: The American heart journal, 2012, Vol.164 (4), p.591-599
description: Background The optimal revascularization strategy for diabetic patients with multivessel coronary artery disease (MVD) remains uncertain for lack of an adequately powered, randomized trial. The FREEDOM trial was designed to compare contemporary coronary artery bypass grafting (CABG) to percutaneous coronary intervention (PCI) with drug-eluting stents in diabetic patients with MVD against a background of optimal medical therapy. Methods A total of 1,900 diabetic participants with MVD were randomized to PCI or CABG worldwide from April 2005 to March 2010. FREEDOM is a superiority trial with a mean follow-up of 4.37 years (minimum 2 years) and 80% power to detect a 27.0% relative reduction. We present the baseline characteristics of patients screened and randomized, and provide a comparison with other MVD trials involving diabetic patients. Results The randomized cohort was 63.1 ± 9.1 years old and 29% female, with a median diabetes duration of 10.2 ± 8.9 years. Most (83%) had 3-vessel disease and on average took 5.5 ± 1.7 vascular medications, with 32% on insulin therapy. Nearly all had hypertension and/or dyslipidemia, and 26% had a prior myocardial infarction. Mean hemoglobin A1c was 7.8 ± 1.7 mg/dL, 29% had low-density lipoprotein
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0002-8703
fulltext: fulltext
issn:
  • 0002-8703
  • 1097-6744
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.4669318
LOCALfalse
PrimoNMBib
record
control
sourceidgale_proqu
recordidTN_cdi_proquest_miscellaneous_1112679740
sourceformatXML
sourcesystemPC
galeidA305237368
sourcerecordidA305237368
originalsourceidFETCH-LOGICAL-1533t-e538603ac73ed4c7c31e89d90d4f1ecc3953bd283d9cfee1c8002aa97e6e95b63
addsrcrecordideNp9kmGLEzEQhhdRvPP0B_hFAiKcH1qTzW6ye4Jw9FoV7iic5-eQZmfb1OxuL8lW6h_z7zlLq8VDJISZhOcdJpM3SV4yOmaUiXfrsV6txyll6ZiKMYZHySmjpRwJmWWPk1NKaToqJOUnybMQ1ngUaSGeJicpp0KWrDxNft6tgMz62Hsgt9OtDqZ32tsfOtquJXjh-n1qW7LBDNoYyHcbV-TK6gVECKQB52zswwWZb6JttCONbvUSGmRJV5Ob3kW7hRDAkcoG0AHI-ex2Or2a37wl0VvtLsjE2dYa1Oq2wr203dLrzcoasvFdbR0QHUmIfbUjWNbvnidPau0CvDjEs-TrbHo3-TS6nn_8PLm8HrGc8ziCnBeCcm0khyoz0nAGRVmVtMpqBsbwMueLKi14VZoagJkCR6Z1KUFAmS8EP0vO93WxjfseQlSNDQZfrFvo-qAYYymOUmYU0dcP0HXX-xa7UyynmeCyzOSRWmoHyrZ1F702Q1F1yWmecslFgdT4HxSuChpruhaGkfwtYHuB8V0IHmq18fgXfqcYVYNZ1FqhWdRgFkWFwoCaV4eG-0UD1R_Fb3cg8OYAoC-0q71ujQ1HTuRUljlD7v2eA_yJrQWvgkGnGKisBxNV1dn_tvHhgdoczPANdhCOQ1QBNerL4OrB1CylNMtkxn8BJ9fx2g
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid1504637947
display
typearticle
titleThe Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) trial: Clinical and angiographic profile at study entry
sourceAlma/SFX Local Collection
creatorBansilal, Sameer, MD, MS ; Farkouh, Michael E., MD, MSc ; Hueb, Whady, MD ; Ogdie, May ; Dangas, George, MD, PhD ; Lansky, Alexandra J., MD ; Cohen, David J., MD, MSc ; Magnuson, Elizabeth A., ScD ; Ramanathan, Krishnan, MB, ChB ; Tanguay, Jean-Francois, MD ; Muratov, Victoria ; Sleeper, Lynn A., ScD ; Domanski, Michael, MD ; Bertrand, Michel E., MD ; Fuster, Valentin, MD, PhD
creatorcontribBansilal, Sameer, MD, MS ; Farkouh, Michael E., MD, MSc ; Hueb, Whady, MD ; Ogdie, May ; Dangas, George, MD, PhD ; Lansky, Alexandra J., MD ; Cohen, David J., MD, MSc ; Magnuson, Elizabeth A., ScD ; Ramanathan, Krishnan, MB, ChB ; Tanguay, Jean-Francois, MD ; Muratov, Victoria ; Sleeper, Lynn A., ScD ; Domanski, Michael, MD ; Bertrand, Michel E., MD ; Fuster, Valentin, MD, PhD
descriptionBackground The optimal revascularization strategy for diabetic patients with multivessel coronary artery disease (MVD) remains uncertain for lack of an adequately powered, randomized trial. The FREEDOM trial was designed to compare contemporary coronary artery bypass grafting (CABG) to percutaneous coronary intervention (PCI) with drug-eluting stents in diabetic patients with MVD against a background of optimal medical therapy. Methods A total of 1,900 diabetic participants with MVD were randomized to PCI or CABG worldwide from April 2005 to March 2010. FREEDOM is a superiority trial with a mean follow-up of 4.37 years (minimum 2 years) and 80% power to detect a 27.0% relative reduction. We present the baseline characteristics of patients screened and randomized, and provide a comparison with other MVD trials involving diabetic patients. Results The randomized cohort was 63.1 ± 9.1 years old and 29% female, with a median diabetes duration of 10.2 ± 8.9 years. Most (83%) had 3-vessel disease and on average took 5.5 ± 1.7 vascular medications, with 32% on insulin therapy. Nearly all had hypertension and/or dyslipidemia, and 26% had a prior myocardial infarction. Mean hemoglobin A1c was 7.8 ± 1.7 mg/dL, 29% had low-density lipoprotein <70 mg/dL, and mean systolic blood pressure was 134 ± 20 mm Hg. The mean SYNTAX score was 26.2 with a symmetric distribution. FREEDOM trial participants have baseline characteristics similar to those of contemporary multivessel and diabetes trial cohorts. Conclusions The FREEDOM trial has successfully recruited a high-risk diabetic MVD cohort. Follow-up efforts include aggressive monitoring to optimize background risk factor control. FREEDOM will contribute significantly to the PCI versus CABG debate in diabetic patients with MVD.
identifier
0ISSN: 0002-8703
1EISSN: 1097-6744
2DOI: 10.1016/j.ahj.2012.06.012
3PMID: 23067919
4CODEN: AHJOA2
languageeng
publisherNew York, NY: Elsevier Inc
subjectAbridged Index Medicus ; Australasia ; Biological and medical sciences ; Cardiology. Vascular system ; Cardiovascular ; Cardiovascular system ; Care and treatment ; Clinical trials ; Coronary Artery Bypass ; Coronary Artery Disease - pathology ; Coronary Artery Disease - surgery ; Coronary vessels ; Diabetes ; Diabetes Mellitus, Type 2 - complications ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - epidemiology ; Diabetes therapy ; Diabetes. Impaired glucose tolerance ; Diabetic Angiopathies - pathology ; Diabetic Angiopathies - surgery ; Diabetics ; Drug therapy ; Drug-Eluting Stents ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Europe ; Female ; Heart attacks ; Humans ; Investigative techniques, diagnostic techniques (general aspects) ; Male ; Medical research ; Medical sciences ; Medicine, Experimental ; Middle Aged ; Mortality ; Myocardial Infarction - prevention & control ; North America ; Radiodiagnosis. Nmr imagery. Nmr spectrometry ; South America ; Stroke - prevention & control
ispartofThe American heart journal, 2012, Vol.164 (4), p.591-599
rights
0Mosby, Inc.
12012 Mosby, Inc.
22015 INIST-CNRS
3Copyright © 2012 Mosby, Inc. All rights reserved.
4COPYRIGHT 2012 Elsevier B.V.
5Copyright Elsevier Limited Oct 2012
lds50peer_reviewed
oafree_for_read
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26507951$$DView record in Pascal Francis
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23067919$$D View this record in MEDLINE/PubMed
search
creatorcontrib
0Bansilal, Sameer, MD, MS
1Farkouh, Michael E., MD, MSc
2Hueb, Whady, MD
3Ogdie, May
4Dangas, George, MD, PhD
5Lansky, Alexandra J., MD
6Cohen, David J., MD, MSc
7Magnuson, Elizabeth A., ScD
8Ramanathan, Krishnan, MB, ChB
9Tanguay, Jean-Francois, MD
10Muratov, Victoria
11Sleeper, Lynn A., ScD
12Domanski, Michael, MD
13Bertrand, Michel E., MD
14Fuster, Valentin, MD, PhD
title
0The Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) trial: Clinical and angiographic profile at study entry
1The American heart journal
addtitleAm Heart J
descriptionBackground The optimal revascularization strategy for diabetic patients with multivessel coronary artery disease (MVD) remains uncertain for lack of an adequately powered, randomized trial. The FREEDOM trial was designed to compare contemporary coronary artery bypass grafting (CABG) to percutaneous coronary intervention (PCI) with drug-eluting stents in diabetic patients with MVD against a background of optimal medical therapy. Methods A total of 1,900 diabetic participants with MVD were randomized to PCI or CABG worldwide from April 2005 to March 2010. FREEDOM is a superiority trial with a mean follow-up of 4.37 years (minimum 2 years) and 80% power to detect a 27.0% relative reduction. We present the baseline characteristics of patients screened and randomized, and provide a comparison with other MVD trials involving diabetic patients. Results The randomized cohort was 63.1 ± 9.1 years old and 29% female, with a median diabetes duration of 10.2 ± 8.9 years. Most (83%) had 3-vessel disease and on average took 5.5 ± 1.7 vascular medications, with 32% on insulin therapy. Nearly all had hypertension and/or dyslipidemia, and 26% had a prior myocardial infarction. Mean hemoglobin A1c was 7.8 ± 1.7 mg/dL, 29% had low-density lipoprotein <70 mg/dL, and mean systolic blood pressure was 134 ± 20 mm Hg. The mean SYNTAX score was 26.2 with a symmetric distribution. FREEDOM trial participants have baseline characteristics similar to those of contemporary multivessel and diabetes trial cohorts. Conclusions The FREEDOM trial has successfully recruited a high-risk diabetic MVD cohort. Follow-up efforts include aggressive monitoring to optimize background risk factor control. FREEDOM will contribute significantly to the PCI versus CABG debate in diabetic patients with MVD.
subject
0Abridged Index Medicus
1Australasia
2Biological and medical sciences
3Cardiology. Vascular system
4Cardiovascular
5Cardiovascular system
6Care and treatment
7Clinical trials
8Coronary Artery Bypass
9Coronary Artery Disease - pathology
10Coronary Artery Disease - surgery
11Coronary vessels
12Diabetes
13Diabetes Mellitus, Type 2 - complications
14Diabetes Mellitus, Type 2 - drug therapy
15Diabetes Mellitus, Type 2 - epidemiology
16Diabetes therapy
17Diabetes. Impaired glucose tolerance
18Diabetic Angiopathies - pathology
19Diabetic Angiopathies - surgery
20Diabetics
21Drug therapy
22Drug-Eluting Stents
23Endocrine pancreas. Apud cells (diseases)
24Endocrinopathies
25Etiopathogenesis. Screening. Investigations. Target tissue resistance
26Europe
27Female
28Heart attacks
29Humans
30Investigative techniques, diagnostic techniques (general aspects)
31Male
32Medical research
33Medical sciences
34Medicine, Experimental
35Middle Aged
36Mortality
37Myocardial Infarction - prevention & control
38North America
39Radiodiagnosis. Nmr imagery. Nmr spectrometry
40South America
41Stroke - prevention & control
issn
00002-8703
11097-6744
fulltexttrue
rsrctypearticle
creationdate2012
recordtypearticle
recordideNp9kmGLEzEQhhdRvPP0B_hFAiKcH1qTzW6ye4Jw9FoV7iic5-eQZmfb1OxuL8lW6h_z7zlLq8VDJISZhOcdJpM3SV4yOmaUiXfrsV6txyll6ZiKMYZHySmjpRwJmWWPk1NKaToqJOUnybMQ1ngUaSGeJicpp0KWrDxNft6tgMz62Hsgt9OtDqZ32tsfOtquJXjh-n1qW7LBDNoYyHcbV-TK6gVECKQB52zswwWZb6JttCONbvUSGmRJV5Ob3kW7hRDAkcoG0AHI-ex2Or2a37wl0VvtLsjE2dYa1Oq2wr203dLrzcoasvFdbR0QHUmIfbUjWNbvnidPau0CvDjEs-TrbHo3-TS6nn_8PLm8HrGc8ziCnBeCcm0khyoz0nAGRVmVtMpqBsbwMueLKi14VZoagJkCR6Z1KUFAmS8EP0vO93WxjfseQlSNDQZfrFvo-qAYYymOUmYU0dcP0HXX-xa7UyynmeCyzOSRWmoHyrZ1F702Q1F1yWmecslFgdT4HxSuChpruhaGkfwtYHuB8V0IHmq18fgXfqcYVYNZ1FqhWdRgFkWFwoCaV4eG-0UD1R_Fb3cg8OYAoC-0q71ujQ1HTuRUljlD7v2eA_yJrQWvgkGnGKisBxNV1dn_tvHhgdoczPANdhCOQ1QBNerL4OrB1CylNMtkxn8BJ9fx2g
startdate2012
enddate2012
creator
0Bansilal, Sameer, MD, MS
1Farkouh, Michael E., MD, MSc
2Hueb, Whady, MD
3Ogdie, May
4Dangas, George, MD, PhD
5Lansky, Alexandra J., MD
6Cohen, David J., MD, MSc
7Magnuson, Elizabeth A., ScD
8Ramanathan, Krishnan, MB, ChB
9Tanguay, Jean-Francois, MD
10Muratov, Victoria
11Sleeper, Lynn A., ScD
12Domanski, Michael, MD
13Bertrand, Michel E., MD
14Fuster, Valentin, MD, PhD
general
0Elsevier Inc
1Mosby
2Elsevier B.V
3Elsevier Limited
scope
0IQODW
1CGR
2CUY
3CVF
4ECM
5EIF
6NPM
7AAYXX
8CITATION
9BSHEE
103V.
117QO
127RV
137TS
147X7
157XB
1688C
1788E
188AO
198C1
208FD
218FI
228FJ
238FK
248G5
25ABUWG
26AN0
27AZQEC
28BENPR
29DWQXO
30FR3
31FYUFA
32GHDGH
33GNUQQ
34GUQSH
35K9.
36KB0
37M0S
38M0T
39M1P
40M2O
41MBDVC
42NAPCQ
43P64
44PADUT
45PQEST
46PQQKQ
47PQUKI
48PRINS
49Q9U
507X8
sort
creationdate2012
titleThe Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) trial: Clinical and angiographic profile at study entry
authorBansilal, Sameer, MD, MS ; Farkouh, Michael E., MD, MSc ; Hueb, Whady, MD ; Ogdie, May ; Dangas, George, MD, PhD ; Lansky, Alexandra J., MD ; Cohen, David J., MD, MSc ; Magnuson, Elizabeth A., ScD ; Ramanathan, Krishnan, MB, ChB ; Tanguay, Jean-Francois, MD ; Muratov, Victoria ; Sleeper, Lynn A., ScD ; Domanski, Michael, MD ; Bertrand, Michel E., MD ; Fuster, Valentin, MD, PhD
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-1533t-e538603ac73ed4c7c31e89d90d4f1ecc3953bd283d9cfee1c8002aa97e6e95b63
rsrctypearticles
prefilterarticles
languageeng
creationdate2012
topic
0Abridged Index Medicus
1Australasia
2Biological and medical sciences
3Cardiology. Vascular system
4Cardiovascular
5Cardiovascular system
6Care and treatment
7Clinical trials
8Coronary Artery Bypass
9Coronary Artery Disease - pathology
10Coronary Artery Disease - surgery
11Coronary vessels
12Diabetes
13Diabetes Mellitus, Type 2 - complications
14Diabetes Mellitus, Type 2 - drug therapy
15Diabetes Mellitus, Type 2 - epidemiology
16Diabetes therapy
17Diabetes. Impaired glucose tolerance
18Diabetic Angiopathies - pathology
19Diabetic Angiopathies - surgery
20Diabetics
21Drug therapy
22Drug-Eluting Stents
23Endocrine pancreas. Apud cells (diseases)
24Endocrinopathies
25Etiopathogenesis. Screening. Investigations. Target tissue resistance
26Europe
27Female
28Heart attacks
29Humans
30Investigative techniques, diagnostic techniques (general aspects)
31Male
32Medical research
33Medical sciences
34Medicine, Experimental
35Middle Aged
36Mortality
37Myocardial Infarction - prevention & control
38North America
39Radiodiagnosis. Nmr imagery. Nmr spectrometry
40South America
41Stroke - prevention & control
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Bansilal, Sameer, MD, MS
1Farkouh, Michael E., MD, MSc
2Hueb, Whady, MD
3Ogdie, May
4Dangas, George, MD, PhD
5Lansky, Alexandra J., MD
6Cohen, David J., MD, MSc
7Magnuson, Elizabeth A., ScD
8Ramanathan, Krishnan, MB, ChB
9Tanguay, Jean-Francois, MD
10Muratov, Victoria
11Sleeper, Lynn A., ScD
12Domanski, Michael, MD
13Bertrand, Michel E., MD
14Fuster, Valentin, MD, PhD
collection
0Pascal-Francis
1Medline
2MEDLINE
3MEDLINE (Ovid)
4MEDLINE
5MEDLINE
6PubMed
7CrossRef
8Academic OneFile (A&I only)
9ProQuest Central (Corporate)
10Biotechnology Research Abstracts
11Nursing & Allied Health Database
12Physical Education Index
13Health & Medical Collection
14ProQuest Central (purchase pre-March 2016)
15Healthcare Administration Database (Alumni)
16Medical Database (Alumni Edition)
17ProQuest Pharma Collection
18Public Health Database
19Technology Research Database
20Hospital Premium Collection
21Hospital Premium Collection (Alumni Edition)
22ProQuest Central (Alumni) (purchase pre-March 2016)
23Research Library (Alumni Edition)
24ProQuest Central (Alumni Edition)
25British Nursing Database
26ProQuest Central Essentials
27ProQuest Central
28ProQuest Central Korea
29Engineering Research Database
30Health Research Premium Collection
31Health Research Premium Collection (Alumni)
32ProQuest Central Student
33Research Library Prep
34ProQuest Health & Medical Complete (Alumni)
35Nursing & Allied Health Database (Alumni Edition)
36Health & Medical Collection (Alumni Edition)
37Healthcare Administration Database
38Medical Database
39Research Library
40Research Library (Corporate)
41Nursing & Allied Health Premium
42Biotechnology and BioEngineering Abstracts
43Research Library China
44ProQuest One Academic Eastern Edition
45ProQuest One Academic
46ProQuest One Academic UKI Edition
47ProQuest Central China
48ProQuest Central Basic
49MEDLINE - Academic
jtitleThe American heart journal
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Bansilal, Sameer, MD, MS
1Farkouh, Michael E., MD, MSc
2Hueb, Whady, MD
3Ogdie, May
4Dangas, George, MD, PhD
5Lansky, Alexandra J., MD
6Cohen, David J., MD, MSc
7Magnuson, Elizabeth A., ScD
8Ramanathan, Krishnan, MB, ChB
9Tanguay, Jean-Francois, MD
10Muratov, Victoria
11Sleeper, Lynn A., ScD
12Domanski, Michael, MD
13Bertrand, Michel E., MD
14Fuster, Valentin, MD, PhD
formatjournal
genrearticle
ristypeJOUR
atitleThe Future REvascularization Evaluation in patients with Diabetes mellitus: Optimal management of Multivessel disease (FREEDOM) trial: Clinical and angiographic profile at study entry
jtitleThe American heart journal
addtitleAm Heart J
date2012
risdate2012
volume164
issue4
spage591
epage599
pages591-599
issn0002-8703
eissn1097-6744
codenAHJOA2
abstractBackground The optimal revascularization strategy for diabetic patients with multivessel coronary artery disease (MVD) remains uncertain for lack of an adequately powered, randomized trial. The FREEDOM trial was designed to compare contemporary coronary artery bypass grafting (CABG) to percutaneous coronary intervention (PCI) with drug-eluting stents in diabetic patients with MVD against a background of optimal medical therapy. Methods A total of 1,900 diabetic participants with MVD were randomized to PCI or CABG worldwide from April 2005 to March 2010. FREEDOM is a superiority trial with a mean follow-up of 4.37 years (minimum 2 years) and 80% power to detect a 27.0% relative reduction. We present the baseline characteristics of patients screened and randomized, and provide a comparison with other MVD trials involving diabetic patients. Results The randomized cohort was 63.1 ± 9.1 years old and 29% female, with a median diabetes duration of 10.2 ± 8.9 years. Most (83%) had 3-vessel disease and on average took 5.5 ± 1.7 vascular medications, with 32% on insulin therapy. Nearly all had hypertension and/or dyslipidemia, and 26% had a prior myocardial infarction. Mean hemoglobin A1c was 7.8 ± 1.7 mg/dL, 29% had low-density lipoprotein <70 mg/dL, and mean systolic blood pressure was 134 ± 20 mm Hg. The mean SYNTAX score was 26.2 with a symmetric distribution. FREEDOM trial participants have baseline characteristics similar to those of contemporary multivessel and diabetes trial cohorts. Conclusions The FREEDOM trial has successfully recruited a high-risk diabetic MVD cohort. Follow-up efforts include aggressive monitoring to optimize background risk factor control. FREEDOM will contribute significantly to the PCI versus CABG debate in diabetic patients with MVD.
copNew York, NY
pubElsevier Inc
pmid23067919
doi10.1016/j.ahj.2012.06.012
oafree_for_read